PMA device
OCS Heart System
TransMedics, Inc. · Organ Care System (Ocs) Heart System (QIK, Class III) · First FDA decision Apr 27, 2022, newest Apr 27, 2022Heart failure
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
33
Naming "OCS"
MAUDE reports
48
Brand "OCS", since 2015
PubMed studies
9,559
Mentioning "OCS"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing OCS Heart System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- OCS Heart SystemBreakthroughPMA supplement
P180051-S001 · Decided Apr 27, 2022 · 170 days after receipt · Panel Track
Device type: Organ care system (OCS) heart system (QIK) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "OCS", any status and sponsor, newest update first.
- OCS DCD Heart + CAP Continued Follow-UpActive, not recruiting
TransMedicsNot on our public-company list
NCT05741723 · 276 participants (planned) · Start Nov 26, 2019 · Primary completion Oct 2026
Device: OCS Heart · For: Heart Transplant
Sites: La Jolla, California; Palo Alto, California; New Haven, Connecticut · 20 sites in all
32 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "OCS", and for the whole product code for context.
This brand
48 reports: 38 malfunction, 10 injury, 0 death
Whole product code QIK
27 reports: 17 malfunction, 7 injury, 1 death
Newest reports for this brand
- OCS Heart Perfusion SetInjury
3003152463-2026-00014 · Received Oct 15, 2026 · Event dated Sep 17, 2026
Device type: Organ Care System (Ocs) Heart System (QIK)
Device problem as coded: No Flow
Patient problem as coded: Insufficient Information; No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "OCS"[tiab]. The summary above synthesizes these.
- Contraception.
Kubba A, Guillebaud J, Anderson RA, et al. · Lancet · 2000Review
- Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial.
Jackson DJ, Lugogo NL, Gurnell M, et al. · Lancet Respir Med · 2026Multicenter Study, Clinical Trial, Phase III
- Biologics for oral corticosteroid-dependent asthma.
Ylmaz · Allergy Asthma Proc · 2020Review
- [Contraception and hepatogastroenterology].
Grimaud JC, Bourliere M · Fertil Contracept Sex · 1989English Abstract
- Ptpn1 deletion protects oval cells against lipoapoptosis by favoring lipid droplet formation and dynamics.
Barahona I, Rada P, Calero-Pérez S, et al. · Cell Death Differ · 2022Research Support, Non-U.S. Gov't
- Genomic and Molecular Characteristics of Ovarian Carcinosarcoma.
Ramphal K, Hadfield MJ, Bandera CM, et al. · Am J Clin Oncol · 2023Review
- Oxidized Chitosan-Tobramycin (OCS-TOB) Submicro-Fibers for Biomedical Applications.
Li Z, Mei S, Dong Y, et al. · Pharmaceutics · 2022
- Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose.
Domingo C, Maspero JF, Castro M, et al. · J Allergy Clin Immunol Pract · 2022Clinical Trial, Phase III, Randomized Controlled Trial
- Over-the-Counter Access to Oral Contraceptives.
Grossman D · Obstet Gynecol Clin North Am · 2015Research Support, Non-U.S. Gov't, Review
- Managing Corticosteroid-Related Comorbidities in Severe Asthma.
Sood V, Rogers L, Khurana S · Chest · 2021Review
- Error-related brain activity associated with obsessive-compulsive symptoms in youth.
Becker H, Liu Y, Hanna GL, et al. · Brain Behav · 2023Research Support, N.I.H., Extramural
Other devices of this type
Also filed under product code QIK.
- Organ Care System (OCS) Heart SystemTransMedics, Inc. · PMA 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.